The NHS has begun offering home-testing kits for human papillomavirus, or HPV, to millions of women in England who have not attended cervical screening appointments after receiving an invitation, in a move aimed at improving early detection of cervical cancer.
The programme, announced on 25 August 2026, will see nearly 4 million women offered self-testing kits if they have not attended screening, with the service designed to make it easier for more people to complete a test that can identify HPV, a key cause of cervical cancer. The NHS said the rollout starts today and is intended to encourage more women to take part in screening. NHS England news
A simpler route into screening for women who have missed appointments
Cervical screening remains one of the most effective ways to spot risk early, but uptake has long been uneven. By sending kits directly to eligible women who have not responded to invitations, the NHS is hoping to reduce barriers such as time, access, and discomfort around in-clinic sampling.
The move builds on the NHS approach of using screening to detect HPV before changes develop into cancer. Health leaders say the self-testing option could help reach women who may otherwise fall through the gaps in routine screening, though the success of the programme will depend on whether people use the kits and return samples. NHS England August 2026 archive
Part of a wider cancer prevention push
The rollout comes as the NHS continues to expand prevention and early diagnosis efforts across cancer services. In recent weeks, NHS England has also highlighted major screening and treatment initiatives, including increased attention to cancer pathways and patient access to care.
For cervical cancer prevention, the home-testing kits offer a practical alternative to conventional appointments, but they are not a replacement for follow-up care where results are abnormal. The key question now is whether the new programme can improve screening participation at scale and help identify risk earlier in women who have previously been harder to reach.
If uptake is strong, the initiative could become a significant public health tool in England’s cervical cancer strategy, with the potential to improve diagnosis rates and reduce avoidable disease in the years ahead.
